1 / 11

Myelom behandling i pipeline

Myelom behandling i pipeline. Pomalidomide/LoDex vs HiDex: Safety. AEs generally similar between arms and across subgroups Most common grade 3/4 AEs: neutropenia, anemia, thrombocytopenia ≥ grade 3 PN in 15% with Pom plus LoDex vs 11% with HiDex.

preston-hays
Download Presentation

Myelom behandling i pipeline

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Myelom behandling i pipeline

  2. Pomalidomide/LoDex vs HiDex: Safety • AEs generally similar between arms and across subgroups • Most common grade 3/4 AEs: neutropenia, anemia, thrombocytopenia • ≥ grade 3 PN in 15% with Pom plus LoDex vs 11% with HiDex San Miguel J, et al. Lancet Oncol. 2013;14:1055-1066.

More Related